Helicos Sets IPO Terms

Helicos Biosciences Corp., a Cambridge, Mass.-based DNA sequencing company, has set its IPO terms to 5.4 million common shares being offered at between $13 and $15 per share. It plans to trade on the Nasdaq under ticker symbol HLCS, with UBS serving as lead underwriter. The company has raised around $67 million in VC funding from firms like Flagship Ventures (20.6% pre-IPO stake), Atlas Venture (17.6%), Highland Capital Partners (17.6%), MPM Capital (12.9%) and Versant Ventures (9.9%). www.helicosbio.com